Cargando…
Managing Lung Nodules Using Telemedicine and Molecular Biomarkers During the COVID-19 Pandemic
Autores principales: | Springmeyer, Steven C., Jett, James, Bhadra, Krish, Kheir, Fayez, Majid, Adnan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American College of Chest Physicians. Published by Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533686/ https://www.ncbi.nlm.nih.gov/pubmed/33036105 http://dx.doi.org/10.1016/j.chest.2020.05.574 |
Ejemplares similares
-
Letter to Editor: Interpretation and Application of the Likelihood Ratio to Clinical Practice in Thoracic Oncology
por: Springmeyer, Steven, et al.
Publicado: (2022) -
Impact of an integrated classifier using biomarkers, clinical and imaging factors on clinical decisions making for lung nodules
por: Kheir, Fayez, et al.
Publicado: (2023) -
Assessing a biomarker’s ability to reduce invasive procedures in patients with benign lung nodules: Results from the ORACLE study
por: Pritchett, Michael A., et al.
Publicado: (2023) -
Bronchoscopic transparenchymal nodule access in the diagnosis and management of pulmonary nodules
por: Zhang, Quncheng, et al.
Publicado: (2023) -
Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial
por: Silvestri, Gerard A., et al.
Publicado: (2018)